Autologous stem cell transplantation for multiple myeloma in patients over 70 years: A matched comparison with patients under 65 years  by Kumar, S. et al.
We compared outcomes of 141 consecutive patients who re-
ceived allogeneic SCT between 1997 and 2004 with either MA
or NMA conditioning to treat non-Hodgkin (MA 62; NMA 
53) or Hodgkin (MA  3; NMA  23) lymphoma. NMA
patients were older [MA: 42 years (4–58); NMA: 48 years
(19–66)] and more recently transplanted [1997–2000: MA  31;
NMA  10; 2001–2004: MA  34; NMA  66]. Cord blood was
used more frequently in the NMA cohort [MA: 6 (9%); NMA:
33 (43%)]. NMA patients had more advanced disease with 57
(75%) in second or greater partial remission (PR) versus 37
(57%) MA patients. Those in complete remission comprised 12
(16%) patients in the NMA cohort and 17 (26%) in the MA
cohort. The remainder were in ﬁrst PR. Thirty patients (39%),
all NMA, had prior autologous transplants. Conditioning regi-
mens consisted of CyTBI, BuCy, or Fludarabine (75 mg/m2)
Cy(120 mg/kg) TBI 13.2Gy for MA and TBI 2.0Gy plus either
Fludarabine (200 mg/m2) Cy (50 mg/kg), Bu (8 mg/kg) Flu, or
Bu Cladrabine(50 mg/m2) for NMA. GVHD prophylaxis was
primarily cyclosporine (CSA)/methotrexate in the MA cohort
(n  59) and CSA/mycophenolate mofetil in the NMA cohort
(n  76). Results are shown in Table 1. In the evaluable
population, primary neutrophil engraftment at day 28 was not
different between the MA and NMA cohorts; however, time to
ANC 500 was signiﬁcantly shorter in the NMA population.
One year treatment related mortality (TRM) was signiﬁcantly
lower for patients in the NMA cohort but the risk of relapse at
1 year was higher. Acute GVHD grade II-IV and grade III-IV
did not differ nor was there a difference in the cumulative
incidence of chronic GVHD at 1 year. Overall survival (OS) at
1 year was lower in the MA cohort but similar by 3 years of
follow-up. Disease free survival (DFS) did not differ at 1 or 3
years. Year of transplant, recipient age, stem cell source, and
related donor were not predictive of OS or DFS. For the NMA
patients, there was a suggestion that those with low grade
lymphoma (n  21) were more likely to be alive and disease free
whereas patients with T cell (n  6) or Hodgkin lymphomas
were likely to relapse or die. Prior autologous transplant, stem
cell source, and disease status did not impact outcomes in the
NMA cohort. These results suggest that the greater TRM of a
MA regimen is balanced by a greater risk of relapse with a NMA
regimen in lymphoma patients. Further investigations to deter-
mine appropriate candidates for the NMA approach are ongoing
(Table 1).
Table 1. Results
Myeloablative
(n  65)
Non-
myeloablative
(n  76) P-value
Cumulative Incidence
of Neutrophil
Engraftment at
day 28 (95% CI)
95% (89–100) 95% (90–100) NS
Days to ANC >500/
L (range)
16 (11–28) 9 (0–28) <0.01
TRM at 1 year 40% (28–52) 17% (9–26) <0.01
Relapse at 1 year 14% (5–22) 37% (25–48) 0.02
Grade II–IV acute
GVHD
43% (30–56) 58% (45–71) NS
Grade III–IV acute
GVHD
14% (6–22) 25% (15–35) NS
Chronic GVHD at 1
year
32% (20–45) 46% (33–59) NS
Median follow-up of
Survivors
{months(range)}
33 (12–66) 24 (10–49) 0.04
Overall Survival
1 year 54% (42–62) 66% (55–76) 0.07
3 years 48% (35–60) 38% (21–55) NS
Disease Free Survival
1 year 46% (34–58) 46% (35–57) NS
3 years 41% (29–54) 25% (11–39) NS
MA: n  29; NMA: n  40
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Background: Autologous stem cell transplantation (ASCT) pro-
longs survival in patients (pts) with multiple myeloma (MM) as
shown by randomized trials. However, most studies included
younger pts, usually 65 or less, and the outcome for older pts,
especially those over 70, is unclear. We retrospectively reviewed
our experience with ASCT for MM in pts over 70 years.Methods:
We identiﬁed 35 pts with MM who were 70 years at the time of
their ASCT. We matched them to 70 pts (two matches per pt),
based on status at transplant (primary refractory, plateau phase,
relapse off therapy, or relapse on therapy), Durie Salmon stage,
high or low labeling index, conventional cytogenetics (abnormal vs
normal), presence of circulating plasma cells at time of stem cell
collection, in that order of priority. Results: The median age of
the groups were 55.3 (range, 37.3–64.8) and 71.7 (70–75.8) years
at transplant. The median time to transplant from diagnosis was
similar (6.4 for the older pts compared to 6.9 mos for the other,
P NS). Ten of the 35 older pts received reduced dose melphalan
(140 mg/2) compared to 3 pts in the control group; P  .01. The
median follow up from transplant was 10.1 months for the older pts
compared to 18 months for the control group. The overall re-
sponse rate was similar (97.1% for the older pts compared to
95.5% for the control group). Eleven (31%) of the older pts and 17
(24%) of the control pts achieved a CR (P  NS). The post
transplant progression free survival estimate at 1 year post trans-
plant was 65.3% for the older pts compared to 66% for the control
group (P  .3). The 2-year estimated overall survival from trans-
plant was similar; 58% for the older pts compared to 67% for the
control group. The overall survival from diagnosis was similar for
the two groups (P  .6). The median number of days hospitalized
was 9 days for the older population compared to 5 days for the
control group (P .37). Four pts died within the ﬁrst one hundred
days, one among the older patient group. Conclusions: ASCT is
feasible in selected pts with MM over 70 years. It is likely that older
pts were selected based on their overall performance status, a factor
that is difﬁcult to analyze in this retrospective review. Nearly 70%
of the elderly pts received full dose melphalan for conditioning
(200 mg/m2). The toxicity of transplant and outcome appears to be
similar to the younger pts. Pts with MM should not be excluded
from ASCT solely on the basis of their age.
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PRE-TRANSPLANT POSITIVE PET/GALLIUM SCANS PREDICT POOR
OUTCOME IN RELAPSED/REFRACTORY HODGKIN LYMPHOMA (HL)
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Champlin, R.1, Fayad, L.1 University of Texas/M. D. Anderson Cancer
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High dose chemotherapy followed by autologous stem cell trans-
plantion (SCT) has become the standard of care in patients (pts)
with relapsed or refractory HL. Chemosensitivity, assessed by
conventional tomography, has been correlated with better disease
free survival (DFS) and outcome. We assessed the value of func-
tional imaging (FI) in pts with HL referred to MDACC and
treated with high dose chemotherapy followed by SCT from De-
cember 1999 to May 2004. Twohundred ﬁfteen pts, male 60%,
median age 31 years, (range 10–76), with nodular sclerosis type
90%, were diagnosed at stages I (2%), II (43%), III (32%), and IV
(23%). Eighty-six percent of the pts were treated with ABVD-
based regimens, 45% received adjuvant radiation therapy. Thirty-
one percent of the pts were primary refractory. Most of the pts
(90%) were salvaged with ESHAP chemotherapy, and the prepar-
ative regimen was BEAM in 80%. At the time of salvage therapy,
B symptoms were present in 60% of the pts, extra-nodal disease
was documented in 24%, and relapse beyond 12 months of re-
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